EyePoint (EYPT) Total Current Liabilities (2011 - 2026)
EyePoint (EYPT) reported Total Current Liabilities of $37.5 million for Q1 2026, down 10.12% on a YoY basis from $41.7 million in Q1 2025, and up 1.18% sequentially from $37.0 million in Q4 2025.
EyePoint (EYPT) Total Current Liabilities (2011 - 2026) Analysis & Trends
EyePoint (EYPT) has 16 years of Total Current Liabilities data on file, last reported at $37.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 10.12% year-over-year to $37.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.5 million (down 10.12% YoY), and the FY2025 full-year result was $37.0 million, down 24.51% from the prior year.
- Total Current Liabilities climbed to $37.5 million in Q1 2026, from $37.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $68.9 million in Q2 2023 to a low of $27.2 million in Q1 2023.
- A 5-year average of $44.7 million and a median of $37.5 million in 2026 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities jumped 137.86% in 2022 and plunged 46.58% in 2025, its largest moves.
- Tracing EYPT's Total Current Liabilities over 5 years: stood at $34.5 million in 2022, then jumped by 83.17% to $63.3 million in 2023, then dropped by 22.47% to $49.0 million in 2024, then declined by 24.51% to $37.0 million in 2025, then grew by 1.18% to $37.5 million in 2026.
- Business Quant data shows EYPT's Total Current Liabilities at $37.5 million in Q1 2026, $37.0 million in Q4 2025, and $30.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 37.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.46 Mn |
| Dec 31, 2025 | 37.02 Mn |
| Sep 30, 2025 | 30.09 Mn |
| Jun 30, 2025 | 33.18 Mn |
| Mar 31, 2025 | 41.68 Mn |
| Dec 31, 2024 | 49.05 Mn |
| Sep 30, 2024 | 48.79 Mn |
| Jun 30, 2024 | 62.10 Mn |
| Mar 31, 2024 | 62.58 Mn |
| Dec 31, 2023 | 63.26 Mn |
| Sep 30, 2023 | 63.90 Mn |
| Jun 30, 2023 | 68.92 Mn |
| Mar 31, 2023 | 27.24 Mn |
| Dec 31, 2022 | 34.54 Mn |
| Sep 30, 2022 | 34.26 Mn |
| Jun 30, 2022 | 33.39 Mn |
| Mar 31, 2022 | 31.97 Mn |
| Dec 31, 2021 | 23.66 Mn |
| Sep 30, 2021 | 19.93 Mn |
| Jun 30, 2021 | 16.25 Mn |